Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy

Targeting the BCL-X(L) pathway has demonstrated the ability to overcome Janus kinase inhibitor resistance in preclinical models. This phase II trial investigated the efficacy and safety of adding BCL-X(L)/BCL-2 inhibitor navitoclax to ruxolitinib therapy in patients with myelofibrosis with progressi...

Descripción completa

Detalles Bibliográficos
Autores principales: Harrison, Claire N., Garcia, Jacqueline S., Somervaille, Tim C.P., Foran, James M., Verstovsek, Srdan, Jamieson, Catriona, Mesa, Ruben, Ritchie, Ellen K., Tantravahi, Srinivas K., Vachhani, Pankit, O'Connell, Casey L., Komrokji, Rami S., Harb, Jason, Hutti, Jessica E., Holes, Leanne, Masud, Abdullah A., Nuthalapati, Silpa, Potluri, Jalaja, Pemmaraju, Naveen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9113204/
https://www.ncbi.nlm.nih.gov/pubmed/35180010
http://dx.doi.org/10.1200/JCO.21.02188

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9113204/
https://www.ncbi.nlm.nih.gov/pubmed/35180010
http://dx.doi.org/10.1200/JCO.21.02188

Ejemplares similares